Want to see NAMS full AI Analyst Report?
NewAmsterdam Pharma Company (NAMS) Ownership - Who Owns NewAmsterdam Pharma Company?
NewAmsterdam Pharma Company (NAMS) Ownership Overview
- 0.37% Insiders
- 21.62% Mutual Funds
- 0.28% Other Institutional Investors
- 1.99% ETFs
- 75.74% Public Companies and Individual Investors
The ownership structure of NewAmsterdam Pharma Company (NAMS) stock is a mix of institutional, retail, and individual investors. Approximately 23.89% of the company’s stock is owned by Institutional Investors, 0.37% is owned by Insiders, and 75.74% is owned by Public Companies and Individual Investors.
The ownership structure of NewAmsterdam Pharma Company (NAMS) stock is a mix of institutional, retail, and individual investors. Approximately 23.89% of the company’s stock is owned by Institutional Investors, 0.37% is owned by Insiders, and 75.74% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Sep 08, 2026 | John Smither | $40,512 | |
| Aug 24, 2026 | Kastelein Johannes Jacob Pieter | $3,363,750 | |
| Jul 21, 2026 | Kooij Louise Frederika | $3,185,656 | |
| Jun 23, 2026 | Kooij Louise Frederika | $1,208,159 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|---|---|---|
| Jun 30, 2026 | Gilder Gagnon Howe & Co Llc. | $7,593,732 | |
| Jun 30, 2026 | Woodline Partners Lp | $25,501,852 | |
| Jun 30, 2026 | Maverick Capital Ltd | $110,745,810 | |
| Jun 30, 2026 | $36,050,488 |
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Peter Kolchinsky | 9,550,191 | Institution | 7.99% | 191,576,831 |
| Smallcap World Fund Inc | 9,266,080 | Institution | 7.75% | 185,877,565 |
| James E. Flynn | 4,264,789 | Institution | 3.57% | 85,551,667 |
| Andreas Halvorsen | 4,203,567 | Institution | 3.52% | 84,323,554 |
| Lee Ainslie | 3,267,802 | Institution | 2.73% | 65,552,108 |
| Stanley Druckenmiller | 3,070,146 | Institution | 2.57% | 61,587,129 |
| Fidelity Rutland Square Trust Ii | 2,289,295 | Institution | 1.92% | 45,923,258 |
| Fidelity Contrafund | 2,066,978 | Institution | 1.73% | 41,463,579 |
| Fidelity Select Portfolios | 1,503,700 | Institution | 1.26% | 30,164,222 |
| Fidelity Securities Fund | 1,025,790 | Institution | 0.86% | 20,577,347 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Smallcap World Fund Inc | 9,266,080 | Institution | 7.75% | 185,877,565 |
| Fidelity Rutland Square Trust Ii | 2,289,295 | Institution | 1.92% | 45,923,258 |
| Fidelity Contrafund | 2,066,978 | Institution | 1.73% | 41,463,579 |
| Fidelity Select Portfolios | 1,503,700 | Institution | 1.26% | 30,164,222 |
| Fidelity Securities Fund | 1,025,790 | Institution | 0.86% | 20,577,347 |
| New Economy Fund | 957,477 | Institution | 0.80% | 19,206,989 |
| T. Rowe Price Health Sciences Fund, Inc. | 912,500 | Institution | 0.76% | 18,304,750 |
| Fidelity Advisor Series Vii | 868,000 | Institution | 0.73% | 17,412,080 |
| Fidelity Concord Street Trust | 656,935 | Institution | 0.55% | 13,178,116 |
| Prudential Sector Funds, Inc. | 534,102 | Institution | 0.45% | 10,714,086 |
Top ETF Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Capital Group, CGMM ETF | 773,400 | Institution | 0.65% | 16,055,784 |
| iShares, IBB ETF | 603,660 | Institution | 0.50% | 12,109,420 |
| Vanguard, VHT ETF | 196,630 | Institution | 0.16% | 4,782,042 |
| ALPS, SBIO ETF | 146,386 | Institution | 0.12% | 2,936,503 |
| iShares, DE:OM3E ETF | 98,814 | Institution | 0.08% | 2,051,379 |
| Fidelity, FFSM ETF | 51,551 | Institution | 0.04% | 1,306,302 |
| iShares, ESML ETF | 49,988 | Institution | 0.04% | 1,002,759 |
| Capital Group, TSE:CAPG ETF | 42,895 | Institution | 0.04% | 2,061,726 |
| Fidelity, ONEQ ETF | 34,876 | Institution | 0.03% | 724,026 |
| Fidelity, FHLC ETF | 32,715 | Institution | 0.03% | 679,163 |
FAQ
Who Owns NewAmsterdam Pharma Company (NAMS)?
According to the latest TipRanks data, approximately 23.89% of the company's stock is held by institutional investors, 0.37% is held by insiders, and 75.74% is held by public companies and individual investors.
What percentage of NewAmsterdam Pharma Company (NAMS) stock is held by institutional investors?
According to the latest TipRanks data, approximately 23.89% of NewAmsterdam Pharma Company (NAMS) stock is held by institutional investors: 21.62% by mutual funds, 1.99% by ETFs and 0.28% by other institutional investors.
What percentage of NewAmsterdam Pharma Company (NAMS) stock is held by retail investors?
According to the latest TipRanks data, approximately 75.74% of NewAmsterdam Pharma Company (NAMS) stock is held by public companies and individual investors.
Who owns the most shares of NewAmsterdam Pharma Company (NAMS)?
Peter Kolchinsky owns the most shares of NewAmsterdam Pharma Company (NAMS).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.